KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Investments (2017 - 2025)

Nektar Therapeutics has reported Long-Term Investments over the past 13 years, most recently at $5.4 million for Q2 2025.

  • Quarterly results put Long-Term Investments at $5.4 million for Q2 2025, down 72.32% from a year ago — trailing twelve months through Jun 2025 was $5.4 million (down 72.32% YoY), and the annual figure for FY2024 was $12.2 million, down 52.69%.
  • Long-Term Investments for Q2 2025 was $5.4 million at Nektar Therapeutics, up from $2.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for NKTR hit a ceiling of $96.1 million in Q1 2021 and a floor of $2.0 million in Q1 2025.
  • Median Long-Term Investments over the past 5 years was $25.8 million (2023), compared with a mean of $31.2 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 48.31% in 2021 and later tumbled 94.51% in 2025.
  • Nektar Therapeutics' Long-Term Investments stood at $64.8 million in 2021, then tumbled by 86.23% to $8.9 million in 2022, then soared by 189.26% to $25.8 million in 2023, then plummeted by 52.69% to $12.2 million in 2024, then tumbled by 56.04% to $5.4 million in 2025.
  • The last three reported values for Long-Term Investments were $5.4 million (Q2 2025), $2.0 million (Q1 2025), and $12.2 million (Q4 2024) per Business Quant data.